HPV Self-sampling Cost Effectiveness Model

Description

The Department of Health and Social Care has appointed an experienced supplier to undertake a piece of cost-effectiveness modelling to understand the conditions under which harms will outweigh benefits for the offer of HPV self-sampling in the UK. Lot 1: The HPV self-sampling ISE will offer a portion of women eligible for cervical screening in England the choice between a clinician taken sample and a self-sample for HPV.<br/>The UK NSC has appointed the University of Sydney to undertake a piece of cost-effectiveness modelling to understand the conditions under which harms will outweigh benefits for the offer of HPV self-sampling in the UK. This is particularly important given that testing for HPV on a vaginal/urine self-sample could be slightly less sensitive than a clinician taken cervical sample. Therefore, modelling is required to understand how the self-sampling offer under different uptake scenarios could impact on the number of screen-detected HPV and treated cervical lesion.<br/>Contract term: 18 months with the option to extend for a period of up to 6 months.<br/>Contract value (including extensions): £249,876 excluding VAT (£299,852 including VAT).